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A mutation of the p53 tumour suppresser gene is the most
common genetic abnormality in solid human malignancies
(Hollstein et al, 1991). p53 is a transcription factor that regulates
cell growth through a cell-cycle checkpoint, which then insures
appropriate cell replication and division. Mutant p53 protein
changes its conformation and lacks both DNA binding capability
and suppressor activity for cell growth. The mutant p53 protein
has a prolonged half-life and thus the detection of p53 protein by
immunohistochemistry may indicate the presence of p53 muta-
tions (Rogel et al, 1985; Hall and Lane, 1994). Recent studies
demonstrated a good correlation in oesophageal carcinoma
between immunohistochemical p53 protein accumulation and the
presence of p53 gene mutations (Bennett et al, 1991; Wagata et al,
1993; Gao et al, 1994). The timing of such p53 alterations on
carcinogenesis and progression may vary among tumours. In
oesophageal cancer, the p53 mutational events occur at an early
stage of carcinogenesis, including dysplasia which could be
considered precancerous lesions of oesophageal cancer (Bennett et
al, 1992; Wang et al, 1993; Gao et al, 1994).
Squamous epithelial dysplasia is frequently encountered in the
oesophagus with squamous cell carcinoma and is often observed
multifocally. We have previously performed serial histopath-
ological investigations for oesophageal carcinomatous lesions, and
a close relationship was observed between dysplasia and carci-
noma based on the continuity of dysplastic lesions to the carci-
noma and the multiplicity of these lesions. Many dysplastic lesions
were located separately from the carcinoma (Nagamatsu et al,
1992). In addition, in the cases with dysplastic lesions, the multi-
plicity of squamous cell carcinoma and the intra-epithelial spread
of the main lesion were also more frequently seen (Kuwano et al,
1993; Morita et al, 1994). We also performed a cytophotometric
DNA analysis of chemically induced oesophageal carcinoma in
rats (Koga et al, 1988) and immunohistochemical detection of
proliferating cell nuclear antigen for resected human oesophageal
specimens (Koga et al, 1996), and demonstrated that the biological
nature of dysplasia might well be as serious a lesion as cancer
itself. In view of these results, multifocal dysplastic lesions may
occur independently, some of which may develop and progress to
carcinoma, thus suggesting the concept of ‘field carcinogenesis’.
There have been some reports about the p53 accumulation or
mutational status on the ‘cancerization field’ of oesophageal carci-
noma. p53 alterations of carcinoma and nearby dysplasia were
identical on resected specimens (Vijeyasingam et al, 1994; Shi et
al, 1999). In contrast, discordant mutations were found among
multifocal precancerous lesions obtained from biopsy samples of
symptom-free subjects in China (Wang et al, 1996). Little infor-
mation is available regarding a systematic characterization
concerning the p53 mutational status of the multifocal cancerous
and precancerous lesions on the cancerization field.
Recently, many reports on the prognostic value of p53
mutational status in oesophageal cancer have been published
(Sarbia et al, 1994; Lam et al, 1997; Ikeda et al, 1999; Kanamoto
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1999). The interpretation of these results, however, still remains
controversial. In the current study, the immunostaining of accumu-
lated p53 protein was performed for a large number of sections
divided from the resected human oesophageal specimens, paying
special attention to the continuity of multifocal dysplastic lesions
to a carcinoma within individual oesophageal cancer. Moreover,
the value of p53 expression as a prognostic indicator of long-term
survival in patients of oesophageal carcinoma with dysplasia was
examined. The purpose of this report is to confirm the biological
and clinical significance of p53 alterations in oesophageal field
carcinogenesis.
MATERIALS AND METHODS
Patients and clinical outcome
Four hundred and twenty three patients with primary oesophageal
carcinoma underwent an oesophageal resection in the Second
Department of Surgery, Kyushu University, Fukuoka, Japan, from
January 1982 to December 1993. Among these cases, excluding
287 patients with adenocarcinoma and those undergoing preopera-
tive treatment, we reviewed 136 who had undergone no preopera-
tive treatment.
Formalin-fixed paraffin-embedded blocks of the entire resected
oesophagus were prepared from 5 mm-wide step-sectioned speci-
mens and were stained with haematoxylin and eosin. The number
of various lesions was counted by a histological diagram and their
extent was mapped in two dimensions. Among 136 cases of
oesophageal squamous cell carcinoma, excluding 101 cases
without dysplasia, 35 cases with squamous dysplasia were selected.
The clinicopathological features of these 35 patients were
reported according to the pathological tumour-node-metastasis
(pTNM) classification of the International Union Against Cancer
(Sabin and Wittekind, 1997). The patients were followed up with
systemic examinations. The mean follow-up period was 53.0
months (range 0.7–111.5 months).
Histopathology and tissue selection
For the histological diagnosis of squamous epithelial dysplasia, we
used the criteria defined by the World Health Organization’s
International Histological Classification of Tumours in 1990
(Watanabe et al, 1990). According to these criteria, mild dysplasia
means lesions in which atypical nuclei are limited to the basal
zone and there is an evidence of cytoplasmic maturation superfi-
cially. With increasing grades of dysplasia, a progressive increase
in the proportion of atypical basal cells is observed, until finally
the entire thickness of the epithelium is replaced. Therefore,
moderate dysplasia was diagnosed when an intra-epithelial lesion
similar to mild dysplasia with an atypical proliferative zone
expanding up to one-half the thickness of the epithelium was
found. Severe dysplasia was defined as an intra-epithelial lesion
with an atypical proliferative zone encompassing up to three-quar-
ters of the epithelium. Carcinoma in situ was diagnosed when
atypical immature cells occupied either the whole or almost the
whole thickness of the epithelium but did not invade the basement
membrane below the basal zone.
Next, special attention was paid to the histopathological 
details in order to determine whether or not dysplastic lesions or
carcinomas in situ were contiguous with the areas of main invasive
carcinoma of each case. We immunohistologically investigated
175 sections from 35 cases which included 43 invasive carci-
nomas, 90 lesions of carcinoma in situ, 179 dysplasias and any
remaining normal squamous epithelium adjacent to these lesions
for the accumulation of mutant p53 protein.
Immunohistochemical staining
Mouse anti-human p53 monoclonal antibody (pAb1801, Ab-2;
Oncogene Science, Inc, Uniondale, NY, USA), which detects both
wild and mutant types of human p53 protein, was applied to
paraffin-embedded sections. For p53 immunostaining, the
Histofine method (Nichirei Co. Ltd, Tokyo, Japan) was used. After
dewaxing and rehydration, the antigen retrieval method using a
microwave was performed. The sections were immersed in H2O
and heated for 20 min at 90° C in a microwave oven, and were then
cooled for 30 min at room temperature. After blocking the endoge-
nous peroxidase activity in methanol with 0.3% hydrogen
peroxide for 30 min and washing, the sections were treated with
10% normal rabbit serum for 30 min. Then the primary antibody
for p53 protein was used at a working concentration of 1:100 at
room temperature overnight. After washing, the sections were
incubated for 30 min at room temperature with biotinylated rabbit
anti-mouse immunoglobulin and peroxidase-conjugated strep-
taviden. Next, 0.03% 3,3′ -diaminobenzidine tetrahydrochloride
and 0.01% hydrogen peroxide in distilled water were used to visu-
alize the positive areas. Methyl green was used for counter-
staining.
Dark brown staining was only observed in the nucleus but not in
the cytoplasm. Lesions, in which all or a majority of the cells
demonstrated dark brown nuclear staining, were counted as posi-
tive. Some sections were subjected to normal serum blocking and
the omission of primary antibody as negative control. Positive
immnostaining was evaluated without any information on the
clinical data of the patients.
Statistical analysis.
Chi-squared tests (or Fisher’s exact test when the expected number
of any cell was smaller than or equal to five) were used to compare
the significance of the p53 status concerning various oesophageal
lesions or clinicopathological parameters.
Survival curves were then plotted with the method of
Kaplan–Meier. The survivals of different groups were compared
by the log-rank test.
RESULTS
p53 expression in various oesophageal lesions
The results of p53 expression in oesophageal squamous cell
dysplasias and invasive carcinomas detected by immunostaining
are shown in Figures 1 and 2 respectively. Regardless of the
variety of lesions, ranging from mild dysplasia to invasive carci-
noma, p53 expression was diffusely detected in the proliferative
atypical nuclei of each lesion (Figures 1 and 2).
The overall frequencies of p53 expression in various
oesophageal lesions are shown in Table 1. No diffuse p53
staining was detected in normal squamous epithelium specimens.
On the other hand, 51.4% (92 of 179 lesions) of dysplasia, 51.0%
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lesions) of invasive carcinoma expressed p53. Moreover, the p53
expression for each degree of dysplasias was 59.7% (40 of 67
lesions) for mild dysplasia, 48.7% (19 of 39 lesions) for
moderate dysplasia and 45.2% (33 of 73 lesions) for severe
dysplasia, respectively. Therefore, as mentioned above, almost
half of all lesions, from mild dysplasia to invasive carcinoma,
expressed p53 protein.
p53 expression in dysplasias associated with
carcinoma
The p53 expression was next compared between dysplasias and
invasive carcinomas for each case. After excluding seven cases
of multiple primary invasive carcinomas with variation in the
p53 expression, 28 cases were evaluated. Among the 28 inva-
sive carcinomas observed in these 28 cases, 14 carcinomas
(50.0%) diffusely expressed p53 protein. In addition, p53
expression was detected in 37 of 39 (94.8%) dysplasias
contiguous to these p53-positive carcinomas, while five of 30
(16.7%) dysplasias contiguous to p53-negative carcinomas
expressed p53 protein. This difference was statistically signifi-
cant (P < 0.0001) (Table 2). An example of p53 expression in
one case, in which the contiguous existence of microinvasive
carcinoma, carcinoma in situ, and epithelial dysplasia was
recognized, is shown in Figure 3. The patterns of p53 expres-
sions in the carcinoma in situ and dysplasia were consistent with
those in invasive carcinomas that were contiguous to each other.
In contrast to the above findings, the isolated dysplasias without
contiguity to the carcinomas in the p53-positive cases, only
expressed p53 protein in 44.0% of lesions (11 of 25 lesions) (Table
3). These data thus suggested that the expression of p53 protein in
the dysplasias depended on the degree of contiguity to the invasive
carcinoma that was considered to be the main lesion in the oesoph-
agus of each patient.
Clinicopathological features and prognoses
Correlation of p53 expression with the clinicopathologic parame-
ters of oesophageal squamous cell carcinomas is shown in Table 4.
In univariate analyses, no significant correlation could be found
between p53 expression and various clinicopathologic parameters,
such as age, sex, size of tumour, location, histological grade, pT,
pN, M, vascular permeation or TNM stage.
No correlation between p53 expression and prognosis was
observed in patients with oesophageal squamous cell carcinoma
and dysplasias (Figure 4).
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Figure 1 (A) Mild dysplasia. An atypical proliferative zone, where the
mitotic activity, hyperchromatism, and nuclear variability can be seen, is
limited to the basal zone. In addition, a cytoplasmic maturation is observed in
a superficial zone. Beneath the dysplastic lesions and carcinoma in situ,
lymphoid proliferation is frequently observed (H&E, × 100).
(B) Immunohistochemical detection of p53 protein in serial sections
corresponding to (A). Immunoreactivity for p53 is located in the nuclei of
atypical proliferative cells in the basal zone (× 100)
Table 1 Expression of p53 in various oesophageal lesions
Number of lesions Positive (%) Negative (%)
Normal epithelium 35 0 (0.0) 35 (100.0)
Dysplasia 179 92 (51.4) 87 (48.6)
Mild dysplasia 67 40 (59.7) 27 (40.3)
Moderate dysplasia 39 19 (48.7) 20 (51.3)
Severe dysplasia 73 33 (45.2) 40 (54.8)
Carcinoma in situ 90 46 (51.0) 44 (49.0)
Invasive carcinoma 43 20 (46.5) 23 (53.5)
Table 2 Expression of p53 in both contiguous dysplasia and carcinoma
Contiguous dysplasia
Carcinoma Dysplasias Positive (%) Negative (%)
(n)
Positive (n = 14) 39 37 (94.8) 2 (5.2)
Negative (n = 14) 30 5 (16.7) 25 (83.3)
Total (n = 28) 69 42 (60.8) 27 (39.1)
P < 0.0001
Table 3 Expression of p53 in isolated dysplasia and carcinoma
Isolated dysplasia
Carcinoma Dysplasias Positive (%) Negative (%)
(n)
Positive (n = 14) 25 11 (44.0) 14 (56.0)
Negative (n = 14) 18 11 (61.1) 7 (38.9)
Total (n = 28) 43 22 (51.2) 21 (48.8)
A
BDISCUSSION
In the current study, the p53 status in oesophageal squamous cell
carcinoma and dysplasia was investigated from the viewpoint of
the continuity of both lesions. The p53 expression in more than
half of all dysplasias apart from the p53-positive carcinomas was
inconsistent with that in the carcinoma. In addition, the p53 posi-
tive rate in these isolated dysplasias was similar to the overall
frequency of expression in dysplasia or carcinoma. Although the
biological nature of dysplasia based on the p53 status might share
strong similarity with that of carcinoma (Wang et al, 1993; Shi et
al, 1999), the origin of the carcinoma and the isolated dysplasias
with discordant p53 immunostaining might be different even in
the individual oesophagus. These findings support the simulta-
neous multifocal origin of oesophageal cancer, and demonstrate
the pattern of p53 alteration in the multicentric or field carcino-
genesis in the oesophagus. Next, we assessed the consistency of
the p53 positivity in dysplasias with that in carcinoma contiguous
to each other, and as a result, 37 of 39 (94.8%) dysplasias
contiguous to p53-positive carcinomas also expressed p53
protein. The p53 positivity in carcinomas and dysplasias that were
contiguous to each other showed a close correlation. Although
identical p53 mutations in carcinoma and nearby dysplasia have
been already reported (Shi et al, 1999), our findings revealed
inconsistent and multifocal origin of p53 alterations which would
contribute to elucidate the mechanism of multicentric or field
carcinogenesis.
Within the limits of the pre-invasive area of the oesophageal
cancer, intratumoural heterogeneity of p53 gene mutation was
recognized (Kawabara et al, 1998). This heterogeneity could be
explained in terms of a collision of multiple clones with different
p53 mutations and/or additional p53 mutations within a single
tumour after clonal expansion. Our previous reports regarding
serial histopathological examinations have shown that the pre-
invasive lesions observed as an intra-epithelial spread was more
frequently seen in the cases with less advanced cancer (Kuwano et
al, 1987; 1988; Tsutsui et al, 1995). We thus speculated that the
intra-epithelial carcinoma might originate from multifocal or field
carcinomatous transformation rather than from an intra-epithelial
spread followed by a progression of the main lesion. As a result,
the intratumoural heterogeneity of p53 gene mutation in pre-inva-
sive carcinoma is presumed to be due to the collision of multiple
clones. In other words, independent and multifocal epithelial
dysplastic lesions can arise simultaneously with or without various
p53 alterations, some of which may develop and progress to
cancer without any additional p53 alteration.
Although p53 alterations play an important role in oesophageal
carcinogenesis, its role in the invasion and metastasis of
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Table 4 Clinicopathological features of p53-positive and -negative groups of
patients with oesophageal squamous cell carcinomas
Parameters p53 accumulation Significance
Positive (%) Negative (%)
Patients (n)1 7 1 8
Mean age (years) 59.8 ± 12.0 67.7 ± 11.4 N.S.
Sex
Male 16 (94.1) 16 (88.9)
Female 1 (5.9) 2 (11.1)
Size of tumour (cm) 3.3 ± 1.5 3.6 ± 2.3 N.S.
Location N.S.
upper 1 (5.9) 3 (16.7)
middle 11 (64.7) 9 (50.0)
lower 5 (29.4) 6 (33.3)
Histology N.S.
G1 (Well) 1 (5.9) 3 (16.7)
G2 (Moderately) 10 (58.8) 9 (50.0)
G3 (Poorly) 6 (35.3) 6 (33.3)
Depth of invasion N.S.
pT1 11 (64.7) 11 (61.1)
pT2 3 (17.6) 4 (22.2)
pT3 2 (11.8) 2 (11.1)
pT4 1 (5.9) 1 (5.6)
Nodal involvement N.S.
pN0 13 (76.5) 16 (88.9)
pN1 4 (23.5) 2 (11.1)
Distant metastases N.S.
M0 17 18
M1 0 0
Vascular permeation N.S.
Present 8 (47.1) 4 (22.2)
Absent 9 (52.9) 14 (77.8)
Stage of TNM N.S.
Stage I 10 (58.8) 11 (61.1)
Stage IIA 2 (11.8) 4 (22.2)
Stage IIB 3 (17.6) 2 (11.1)
Stage III 2 (11.8) 1 (5.6)
Stage IV 0 0 Figure 2 (A) Invasive carcinoma. Moderately differentiated squamous cell
carcinoma with invasion to the deeper portion of the submucosal layer (H&E,
× 90). (B) Immunohistochemical detection of p53 protein. Immunoreactivity
for p53 is diffusely detected in the nuclei of atypical proliferative cells (× 90)
A
Boesophageal carcinomas remains unclear. There have recently
been many reports concerning the prognostic value of the p53
alterations in oesophageal carcinoma (Sarbia et al, 1994; Lam et
al, 1997; Ikeda et al, 1999; Kanamoto et al, 1999; Kobayashi et al,
1999; Shimada et al, 1999; Wang et al, 1999). However, the
reported results are inconsistent. In this study, no significant corre-
lations were found between p53 staining and the clinicopatho-
logical features or patients survival. The prognoses demonstrated
in this study were better than those in other articles, because the
selected patients had been restricted to a rather earlier stage of
oesophageal cancer without any preoperative treatment. Moreover,
all patients analysed in this study had carcinomas coexistent with
dysplasias, which were more frequently seen in the less advanced
oesophageal cancer (Kuwano et al, 1993). As mentioned above,
the p53 alteration in such patients might occur in the early stages
of oesophageal carcinogenesis but not in stages of tumour devel-
opment or progression, thus resulting in no correlation in the prog-
noses. Several studies have emphasized a worse prognosis in stage
II or III oesophageal cancers with p53 mutations (Lam et al, 1997,
Kobayashi et al, 1999). We cannot exclude the possibility that the
p53 mutations may induce a growth capability to tumour cells in
relatively advanced oesophageal cancer and may thus be associ-
ated with a lower patient survival.
In general, the immunohistochemical approach for detecting
p53 alterations must be viewed with care. We cannot rule out the
possibility of non-mutational mechanisms for p53 protein accumu-
lation, such as a stabilization of the wild-type p53 protein (Finlay
et al, 1988; van den Heuvel et al, 1990) or an inactivation of the
enzyme for p53 protein degradation (Ciechanover et al, 1991). In
addition, negative p53 immunostaining does not necessarily rule
out p53 mutations, because allelic loss or frameshift mutations
may not cause any protein accumulation. Nevertheless, the method
of p53 immunostaining is strongly suggested to be useful in this
situation to analyse the p53 inconsistency in the cancerization field
of the individual oesophagus.
In conclusion, the multifocal p53 alterations seen in multicentric
cancerous and precancerous lesions could demonstrate further
evidence for field carcinogenesis of the human oesophagus.
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Figure 3 (A) The contiguous existence of microinvasive carcinoma (MIC), carcinoma in situ (CIS), and epithelial dysplasia (DYSP) in a resected specimen of
the oesophagus (H&E, × 7). (B) Immunohistochemical staining of p53 protein in a serial section (× 7). In this specimen, from microinvasive carcinoma (C) to
contiguous epithelial dysplasia (D), the nuclei of the atypical proliferative cells all presented homogenous immunoreactivity for p53 (C, D × 70)
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Figure 4 Kaplan–Meier survival curves of 35 patients with oesophageal
carcinoma grouped according to the p53 expression. No significant difference
was found between the p53-positive group (n = 17) and the p53-negative
group (n = 18) by the log-rank testTherefore, a careful follow-up by frequent biopsies using endo-
scopic Lugol staining test (Mori et al, 1993) is needed for early
detection of cancer development from these dysplastic lesions,
while it is also important to pay close attention to the multicentric
occurrence of these lesions. Although dysplasia should not be
considered ‘clinical cancer’ since it stays in the epithelium without
invasion, the biological nature of dysplasia may be similar to that
of carcinoma regarding p53 expression. An endoscopic mucosal
resection is thus indicated for both an accurate diagnosis and a
good curative effect, when a p53 abnormality is detected and/or a
diagnosis of carcinoma cannot be ruled out based on the findings
of biopsy specimens.
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